Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Conditions

Neuroblastoma 8Ganglioneuroblastoma 4Triple Negative Breast Neoplasms 3Melanoma 3Lung Neoplasms 3Carcinoma, Non-Small-Cell Lung 2Adenoma, Islet Cell 2Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Resectable Esophageal Cancer 1Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Locally Advanced Pancreatic Adenocarcinoma 1Leukemia, Plasma Cell 1Gliosarcoma 1Glioblastoma 1Endometrial Neoplasms 1Carcinosarcoma 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Merkel Cell 1Carcinoma, Intraductal, Noninfiltrating 1Carcinoma, Hepatocellular 1

Interventions

Specimen Handling 4Magnetic Resonance Spectroscopy 4Temozolomide 3sargramostim 2montanide ISA 51 2lutetium Lu 177 dotatate 2incomplete Freund's adjuvant 2Sunitinib 2Octreotide 2Everolimus 2Colony-Stimulating Factors 2Capecitabine 2sapanisertib 1lanreotide 1fludarabine phosphate 1cabozantinib 1belzutifan 1atezolizumab 1aflibercept 1abemaciclib 1X-Rays 1Salts 1Phantoms, Imaging 1PM 01183 1Methods 1LY2940680 1Interleukin-13 1Injections 1Immunoglobulin G 1Fulvestrant 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Adenoma, Islet Cell × Colony-Stimulating Factors × 1 year × Clear all
NCT06202066 2026-05-28

Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas

Roswell Park Cancer Institute

Phase 2 Recruiting
60 enrolled

Adenoma, Islet Cell

NCT03879694 2026-02-06

Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors

Roswell Park Cancer Institute

Phase 1 Completed
19 enrolled

Adenoma, Islet Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡